CRISPR Therapeutics AG (CRSP) Accumulated Depreciation (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Accumulated Depreciation of $95.3 million for Q1 2026, up 4.71% sequentially from $91.1 million in Q4 2025, and up 23.87% YoY from $77.0 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Accumulated Depreciation (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Accumulated Depreciation for 12 years, with the latest figure at $95.3 million in Q1 2026.
- Quarterly Accumulated Depreciation rose 23.87% year-over-year to $95.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.3 million (up 23.87% YoY) and the FY2025 annual result came in at $91.1 million, up 25.99% from the prior year.
- Accumulated Depreciation rose to $95.3 million in Q1 2026 per CRSP's latest filing, from $91.1 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $95.3 million in Q1 2026 and troughed at $28.0 million in Q3 2022.
- A 5-year average of $60.8 million and a median of $58.3 million in 2024 frame the typical range for Accumulated Depreciation.
- The widest YoY moves for Accumulated Depreciation: up 85.67% in 2022, down 14.8% in 2022.
- Over 5 years, Accumulated Depreciation stood at $33.8 million in 2022, then soared by 57.94% to $53.4 million in 2023, then surged by 35.26% to $72.3 million in 2024, then climbed by 25.99% to $91.1 million in 2025, then increased by 4.71% to $95.3 million in 2026.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $95.3 million, $91.1 million, and $85.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.59 Mn |
| Mar 31, 2026 | 95.34 Mn |
| Dec 31, 2025 | 91.05 Mn |
| Sep 30, 2025 | 85.61 Mn |
| Jun 30, 2025 | 81.60 Mn |
| Mar 31, 2025 | 76.97 Mn |
| Dec 31, 2024 | 72.27 Mn |
| Sep 30, 2024 | 67.79 Mn |
| Jun 30, 2024 | 63.07 Mn |
| Mar 31, 2024 | 58.25 Mn |
| Dec 31, 2023 | 53.43 Mn |
| Sep 30, 2023 | 48.55 Mn |
| Jun 30, 2023 | 43.82 Mn |
| Mar 31, 2023 | 38.87 Mn |
| Dec 31, 2022 | 33.83 Mn |
| Sep 30, 2022 | 27.97 Mn |
| Jun 30, 2022 | 51.09 Mn |
| Mar 31, 2022 | 43.83 Mn |
| Dec 31, 2021 | 37.81 Mn |
| Sep 30, 2021 | 32.83 Mn |